TY - JOUR
T1 - Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
AU - Miura, Tomofumi
AU - Mitsunaga, Shuichi
AU - Ikeda, Masafumi
AU - Shimizu, Satoshi
AU - Ohno, Izumi
AU - Takahashi, Hideaki
AU - Furuse, Junji
AU - Inagaki, Masatoshi
AU - Higashi, Sayumi
AU - Kato, Hiroyuki
AU - Terao, Kimio
AU - Ochiai, Atsushi
N1 - Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/7/25
Y1 - 2015/7/25
N2 - Objectives: High serum level of interleukin 6 (IL-6) is associated with high degree of tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration of clinical characteristics in patients with high IL-6 level. However, IL-6-related factors in patients with treatment-naive advanced pancreatic cancer (PC) have not been established. The goal of this study was to identify IL-6-related factors in patients with advanced PC who were scheduled to undergo first-line chemotherapy. Methods: Patients with treatment-naive advanced PC were eligible for inclusion in this study. Patients who did not receive first-line chemotherapy were excluded. Serum IL-6 levels and clinical parameters were prospectively recorded. Analyses were performed to identify risk factors for high IL-6 levels. Results: Eighty patients were analyzed. IL-6-related factors were advanced age (P < 0.01), the presence of liver metastasis (P < 0.01), the large volume of liver metastasis (P < 0.01), severe fatigue (P = 0.02), high carcinoembryonic antigen levels (P = 0.02), anemia (P < 0.01), and high C-reactive protein levels (P = 0.02) in multivariate analyses. Decreased skeletal muscle mass tended to be associated with high IL-6 levels. Conclusions: High serum IL-6 was related to advanced age, the presence of hepatic metastasis, large tumor burden in liver, severe fatigue, high carcinoembryonic antigen, high C-reactive protein, and anemia in patients with treatment-naive advanced PC.
AB - Objectives: High serum level of interleukin 6 (IL-6) is associated with high degree of tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration of clinical characteristics in patients with high IL-6 level. However, IL-6-related factors in patients with treatment-naive advanced pancreatic cancer (PC) have not been established. The goal of this study was to identify IL-6-related factors in patients with advanced PC who were scheduled to undergo first-line chemotherapy. Methods: Patients with treatment-naive advanced PC were eligible for inclusion in this study. Patients who did not receive first-line chemotherapy were excluded. Serum IL-6 levels and clinical parameters were prospectively recorded. Analyses were performed to identify risk factors for high IL-6 levels. Results: Eighty patients were analyzed. IL-6-related factors were advanced age (P < 0.01), the presence of liver metastasis (P < 0.01), the large volume of liver metastasis (P < 0.01), severe fatigue (P = 0.02), high carcinoembryonic antigen levels (P = 0.02), anemia (P < 0.01), and high C-reactive protein levels (P = 0.02) in multivariate analyses. Decreased skeletal muscle mass tended to be associated with high IL-6 levels. Conclusions: High serum IL-6 was related to advanced age, the presence of hepatic metastasis, large tumor burden in liver, severe fatigue, high carcinoembryonic antigen, high C-reactive protein, and anemia in patients with treatment-naive advanced PC.
KW - anti-IL-6 therapy
KW - cancer cachexia
KW - interleukin 6
KW - pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=84932635849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84932635849&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000335
DO - 10.1097/MPA.0000000000000335
M3 - Article
C2 - 25931255
AN - SCOPUS:84932635849
SN - 0885-3177
VL - 44
SP - 756
EP - 763
JO - Pancreas
JF - Pancreas
IS - 5
ER -
